Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2021 | 2 |
2022 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Clin Cancer Res. 2024 May 1;30(9):1750-1757. doi: 10.1158/1078-0432.CCR-23-2592.
Clin Cancer Res. 2024.
PMID: 38393723
Free PMC article.
Clinical Trial.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS.
Choueiri TK, et al.
Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31.
Lancet Oncol. 2023.
PMID: 37011650
Clinical Trial.
Item in Clipboard
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.
Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.
Stransky LA, et al.
Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119. doi: 10.1073/pnas.2120403119. Epub 2022 Mar 31.
Proc Natl Acad Sci U S A. 2022.
PMID: 35357972
Free PMC article.
Item in Clipboard
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK.
McGregor BA, et al.
JCO Precis Oncol. 2022 Feb;6:e2100448. doi: 10.1200/PO.21.00448.
JCO Precis Oncol. 2022.
PMID: 35171658
Free PMC article.
Clinical Trial.
Item in Clipboard
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators.
Jonasch E, et al.
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
N Engl J Med. 2021.
PMID: 34818478
Free PMC article.
Clinical Trial.
Item in Clipboard
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E.
Choueiri TK, et al.
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
Nat Med. 2021.
PMID: 33888901
Free PMC article.
Clinical Trial.
Item in Clipboard
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA, Perrimon N, Signoretti S, Kaelin WG Jr.
Nicholson HE, et al.
Sci Signal. 2019 Oct 1;12(601):eaay0482. doi: 10.1126/scisignal.aay0482.
Sci Signal. 2019.
PMID: 31575731
Free PMC article.
Item in Clipboard
Cite
Cite